Total Funding
70
47
Total FundingSeries A raised
Growth Score
-15 pts
Heat Score
-21 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
35232
ClostraBio is a biopharma company developing therapeutics for food allergies.
- Cathryn R. Nagler: President and Co-FounderPast Role: Harvard Medical School, Associate Professor of Pediatrics (Immunology)
Jeffrey A. Hubbell: Co-Founder , Board Member
About the Company
ClostraBio develops drugs that can prevent allergic reactions to food. It is dedicated to understanding and treating food allergies and other diseases of the immune system. The company is discovering and developing new therapeutics that modulate the protective ability of the microbe.
ClostraBio’s scientific team has made key discoveries that
highlight the importance of the intestinal microbiota in regulating allergic sensitization to food. The company is committed to a deeper understanding of the role of intestinal microbes in gut barrier function and determining the mechanisms of barrier protection.
Women Founded
